Incidence, patterns, risk factors, and management of immediate hypersensitivity reactions in gynecologic cancer patients receiving paclitaxel -based chemotherapy

Not Applicable

Completed

• Conditions: Patients with cancer; Adverse drug reactions, Malignancy, Paclitaxel, Risk factors, Hypersensitivity

• Registration Number: TCTR20200220001
• Lead Sponsor: no

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-12-01
• Study Start: 2020-02-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 416

Inclusion Criteria

Diagnosis with gynecologic malignancy and received of paclitaxel-based chemotherapy between January 2012 and December 2017.

Exclusion Criteria

HSRs more than one hour after starting paclitaxel administration or had incomplete medical records

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hypersensitivity 6 years Incidence

Secondary Outcome Measures

Name	Time	Method
Risk factor 6 years Number of event